Overall, our data suggest that verproside in YPL-001 is the most effective iridoid for reducing inflammation observed in COPD by inhibiting phospho-activation of PKCδ, one of the most upstream regulators of the NF-κB and EGR-1 pathways (Figure 7). This evidence concerns the gene PRKCD and chronic obstructive pulmonary disease.